Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 15/20 | 0.64 |
| ▸ | CTSL | P07711 | 3/20 | 0.58 |
| ▸ | CTSS | P25774 | 3/20 | 0.58 |
| ▸ | CTSK | P43235 | 3/20 | 0.58 |
| ▸ | CTSH | P09668 | 1/20 | 0.58 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8991592 | 0.95 | CXCR4 (0.64) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL29366767 | 0.91 | CXCR4 (0.59) | CXCR4CXCL8 | |
| SCHEMBL17232032 | 0.90 | CXCR4 (0.63) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL30285072 | 0.88 | CXCR4 (0.60) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL31154425 | 0.86 | CXCR4 (0.65) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL30284926 | 0.86 | CXCR4 (0.59) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL31452901 | 0.85 | CXCR4 (0.67) | CXCR4CXCL8 | |
| SCHEMBL29700788 | 0.84 | CXCR4 (0.67) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL29532761 | 0.84 | CCKBR (0.60) | CXCR4 | |
| SCHEMBL31433225 | 0.84 | CXCR4 (0.65) | CXCR4CTSLCTSSCTSKCTSH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250026787-A1 | PEPTIDES AND METHODS FOR REDUCING SKIN PIGMENTATION | GLO PHARMA, INC. | 2025-01-23 | — | — | US | disclosed |
| US-12162956-B2 | Peptides and methods for reducing skin pigmentation | GLO PHARMA, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2024-11-14 | — | — | US | disclosed |
| EP-4419126-A1 | PHOTOACTIVATABLE ION CHANNEL MODULATOR | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2024-08-28 | — | — | EP | disclosed |
| US-20240190917-A1 | PEPTIDES AND METHODS FOR REDUCING SKIN PIGMENTATION | GLO PHARMA, INC. | 2024-06-13 | — | — | US | disclosed |
| US-20230303984-A1 | Enzymes for Sialylation of Glycans | MOMENTA PHARMACEUTICALS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-11746114-B2 | Thermally sensitive protecting groups for cysteine for peptide cyclization and selective disulfide bond formation | UNIVERSITY OF WINDSOR (CA) | 2023-09-05 | — | — | US | disclosed |
| EP-4198029-A1 | INHIBITORS OF PEPTIDYL ARGININE DEIMINASE (PAD) ENZYMES AND USES THEREOF | University Health Network (CA) | 2023-06-21 | — | — | EP | disclosed |
| WO-2023067366-A1 | PHOTOACTIVATABLE ION CHANNEL MODULATOR | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2023-04-27 | — | — | WO | disclosed |
| CN-115605230-A | Enzymes for sialylation of glycans | 动量制药公司（US） | 2023-01-13 | — | — | CN | disclosed |
| EP-4110391-A1 | ENZYMES FOR SIALYLATION OF GLYCANS | Momenta Pharmaceuticals, Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| CN-110981967-B | Dimer of alpha-conotoxin Mr1.1, synthetic method and application | 中国海洋大学 | 2022-10-14 | — | — | CN | disclosed |
| EP-3337791-B1 | INHIBITORS OF PEPTIDYL ARGININE DEIMINASE (PAD) ENZYMES AND USES THEREOF | UNIV HEALTH NETWORK (CA) | 2022-08-03 | — | — | EP | disclosed |
| US-20220153749-A1 | Thermally Sensitive Protecting Groups for Cysteine for Peptide Cyclization and Selective Disulfide Bond Formation | UNIVERSITY OF WINDSOR (CA) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153749-A1 | Thermally Sensitive Protecting Groups for Cysteine for Peptide Cyclization and Selective Disulfide Bond Formation | PTMS, CTH, VIP | CXCR4 3046/4885CTSL 1778/4885CTSS 2269/4885 |
| US-20240190917-A1 | PEPTIDES AND METHODS FOR REDUCING SKIN PIGMENTATION | MC1R, TYR, MC5R | CXCR4 3150/4885CTSL 1535/4885CTSS 2514/4885 |
| US-11746114-B2 | Thermally sensitive protecting groups for cysteine for peptide cyclization and selective disulfide bond formation | PTMS, CTH, VIP | CXCR4 3046/4885CTSL 1778/4885CTSS 2269/4885 |
| US-12162956-B2 | Peptides and methods for reducing skin pigmentation | MC1R, TYR, MC5R | CXCR4 3150/4885CTSL 1535/4885CTSS 2514/4885 |
| US-20250026787-A1 | PEPTIDES AND METHODS FOR REDUCING SKIN PIGMENTATION | MC1R, TYR, MC5R | CXCR4 3150/4885CTSL 1535/4885CTSS 2514/4885 |
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | SCTR, GIPR, APLNR | CXCR4 1234/4885CTSL 217/4885CTSS 820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.